Information Provided By: 
Fly News Breaks for June 5, 2015
BMRN
Jun 5, 2015 | 05:37 EDT
Barclays analyst Geoff Meacham started shares of BioMarin with an Overweight rating and $150 price target. The drugmaker focused on orphan diseases closed yesterday down $3.31 to $120.46. Meacham sees "multiple value-creating pipeline events" for BioMarin over the next 12 months, with the highest impact asset being drisapersen for the treatment of Duchenne muscular dystrophy. The analyst expects approval by the end of 2015, and models peak sales of over $1B.
News For BMRN From the Last 2 Days
